Introduction
Antithyroid drugs (ATD) are the cornerstone of hyperthyroidism management. Hepatotoxicity due to ATDs can range from mild transaminase elevation to liver transplantation requirement and mortality.
Methods
We conducted a systematic review of PUBMED, SCOPUS and EMBASE on characteristics and outcomes of adults (>18 years) with drug-induced liver injury (DILI) due to ATDs. We defined DILI as bilirubin ≥2.5 mg/dL or INR >1.5 with any rise in ALT, AST, or ALP, or an elevation of ALT or AST >5 times or ALP >2 times the upper limit of normal without jaundice/coagulopathy.
Results
The review included 100 articles describing 271 patients. 148 (70.8%) were female. Mean age was 42.9 ± 17.2 years. Graves’ disease was the most common indication for ATDs. Carbimazole/methimazole (CBM/MMI) was the most common offending agent (55.7%). DILI pattern was hepatocellular in 41.8%, cholestatic in 41.3% and mixed in 16.9%. Outcomes included death in 11.8%, liver transplantation in 6.4%, partial improvement in 2.2% and complete resolution in 79.6% with a median time (IQR) to resolution of 45 (20-90) days. Patients in the PTU group had higher initial bilirubin, initial AST, initial ALT, peak ALT, peak AST, severe and fatal DILI, liver transplantation, and mortality compared to CBZ/MMI. Rechallenge of antithyroid medication was infrequently reported (N = 16) but was successful in 75%.
Conclusion
DILI due to ATDs can present with different patterns and should prompt immediate drug discontinuation. Referral to a hepatologist should be considered if severe, as transplantation is sometimes required. PTU-induced DILI may have worse outcomes than CBM/MMI.